Effect of Guanxin Danshen Formula on diabetic kidney disease in db/db mice through regulation of Nrf2 pathway

ZHANG Bin1,2,3 ZHANG Xue-lian1,2,3 ZHANG Chen-yang1,2,3 SUN Gui-bo1,2,3 SUN Xiao-bo1,2,3

(1.Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China 100193)
(2.Key Laboratory of New Drug Discovery based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing, China 100193)
(3.Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing, China 100193)

【Abstract】Diabetic kidney disease (DKD) has become a primary cause of end-stage kidney disease, without any effective treatment available. In this study, we assessed the protective effect of Guanxin Danshen Formula (GXDSF) on diabetic nephropathy in db/db mice. The db/m and db/db mice were randomly divided into four groups: a control group, a model group, a metformin group, and a GXDSF group. After 8 weeks’ treatment with GXDSF, metformin or normal saline, the mice were sacrificed, and the blood and kidney tissues were collected for further analysis. Compared with the model group, the TG, TCH and LDL levels significantly decreased in the GXDSF group. The results from HE and PAS staining showed that db/db mice exhibited abnormal kidney tissues with increased glomerular volume, basement membrane thickening and mesangial cell proliferation, which could be significantly alleviated by GXDSF treatment. GXDSF treatment also reduced serum creatinine and BUN. Meanwhile, GXDSF treatment markedly elevated the GSH-PX levels, while reduced the LDH and MDA levels in the kidney tissues. Western blot assay showed that GXDSF evidently up-regulated the protein levels of ERα and p-Akt, and subsequently promoted the HO-1 expression mediated by Nrf2. These data collectively indicated that GXDSF protected db/db mice against DN by regulating the ERα and Nrf2-mediated HO-1 expression.

【Keywords】 Guanxin Danshen Formula ; diabetic kidney disease (DKD); oxidative stress; diabetes mellitus; estrogen receptor;


【Funds】 Funding Project of Key Laboratory of Chinese Academy of Medical Sciences (2018PT35030) National Key Research and Development Project (2018YFC1707408) National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2018ZX0971101-009) National Natural Science Foundation of China (81891012)

Download this article


    [1] PAPADOPOULOU-MARKETOU N, PASCHOU S A, MARKETOS N, et al. Diabetic nephropathy in type 1 diabetes [J]. Minerva Med, 2018, 109 (3): 218.

    [2] ZHANG L, LONG J, JIANG W, et al. Trends in chronic kidney disease in China [J]. N Engl J Med, 2016, 375 (9): 905.

    [3] FIORETTO P, MAUER M. Diabetic nephropathy: diabetic nephropathy-challenges in pathologic classification [J]. Nat Rev Nephrol, 2010, 6 (9): 508.

    [4] DING T, WANG S F, ZHANG X Y, et al. Kidney protection effects of dihydroquercetin on diabetic nephropathy through suppressing ROS and NLRP3 inflammasome [J]. Phytomedicine, 2018, 41: 45.

    [5] YUAN Y, SUN H, SUN Z. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN) [J]. Lipids Health Dis, 2017, 16 (1): 126.

    [6] ZHANG B, ZHANG X L, Zhang C Y, et al. Notoginsenoside R1 protects db/db mice against diabetic nephropathy via upregulation of Nrf2-mediated HO-1 expression [J]. Molecules, 2019, 24 (2): 247.

    [7] ABBASI B, GHIASVAND R, MIRLOHI M. Kidney function improvement by soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: a double-blinded randomized controlled trial [J]. Iran J Kidney Dis, 2017, 11 (1): 36.

    [8] LIU C, WANG M. SGLT-2抑制剂在糖尿病肾病中的疗效观察 [J]. Medical Diet and Health, 2019, 24 (18): 101 (in Chinese).

    [9] ZHANG P, ZHANG X, BROWN J, et al. Global healthcare expenditure on diabetes for 2010 and 2030 [J]. Diabetes Res Clin Pract, 2010, 87 (3): 293.

    [10] WADA J, MAKINA H. Inflammation and the pathogenesis of diabetic nephropathy [J]. Clin Sci (Lond), 2013, 124 (3):139.

    [11] MAO Z M, HUANG Y R, WAN Y G, et al. Regulative mechanisms of oxidative stress in kidney in diabetic nephropathy and interventional effects of Chinese herbal medicine [J]. China Journal of Chinese Materia Medica, 2014, 39 (19): 3707 (in Chinese).

    [12] FAN Y, LEE K, WANG N, et al. The role of endoplasmic reti-culum stress in diabetic nephropathy [J]. Curr Diab Rep, 2017, 17 (3): 17.

    [13] WU W, LIU B H, WAN Y G, et al. Triptolide inhibits NLRP3 inflammasome activation and ameliorates podocyte epithelial-mesenchymal transition induced by high glucose [J]. China Journal of Chinese Materia Medica, 2019, 44 (24): 5457 (in Chinese).

    [14] WANG W W, HAN W B, WAN Y G, et al. Molecular regulative mechanisms of NLRP3 inflammasome activation in diabetic nephropathy and interventional effects of Chinese herbal medicine [J]. China Journal of Chinese Materia Medica, 2020, 45 (1): 7 (in Chinese).

    [15] LIU X L, LIU W P, WANG L L, et al. Effects of flavonoids from Pyrrosiae folium on pathological changes and inflammatory response of diabetic nephropathy [J]. China Journal of Chinese Materia Medica, 2018, 43 (11): 2352 (in Chinese).

    [16] NI Z, GUO L, LIU F, et al. Allium tuberosum alleviates diabetic nephropathy by suppressing hyperglycemia-induced oxidative stress and inflammation in high fat diet/streptozotocin treated rats [J]. Biomed Pharmacother, 2019, 112: 108678.

    [17] SONG D, YIN L, WANG C, et al. Zhenqing recipe attenuates non-alcoholic fatty liver disease by regulating the SIK1/CRTC2 signaling in experimental diabetic rats [J]. BMC Complement Med Ther, 2020, 20: 27.

    [18] CHEN J, DENG J, ZHANG Y Y, et al. Study on regulatory effect of Danshensu on lipid metabolism of hyperlipidemia rats [J]. China Journal of Chinese Materia Medica, 2015, 40 (2): 313 (in Chinese).

    [19] MISRA A, KUMAR S, KISHORE VIKRAM N, et al. The role of lipids in the development of diabetic microvascular complications: implications for therapy [J]. Am J Cardiovasc Drugs, 2003, 3 (5): 325.

    [20] LEE W, LIU S, CHIANG C. Aryl hydrocarbon receptor deficiency attenuates oxidative stress-related mesangial cell activation and macrophage infiltration and extracellular matrix accumulation in diabetic nephropathy [J]. Antioxid Redox Signal, 2016, 24 (4): 217.

    [21] ZHU C, WANG S, WANG B, et al. 17β-estradiol up-regulates Nrf2 via PI3K/AKT and estrogen receptor signaling pathways to suppress light-induced degeneration in rat retina [J]. Neuroscience, 2015, 304: 328.

    [22] WU J, WILLIAMS D, WALTER G A, et al. Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells [J]. Exp Cell Res, 2014, 328 (2): 351.

    [23] DENG X, XING X, SUN G, et al. Guanxin Danshen Formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor beta [J]. Front Pharmacol, 2017, 8: 777.

    [24] WU P, YAN Y, MA L, et al. Effects of the Nrf2 protein modulator salvianolic acid a alone or combined with metformin on diabetes-associated macrovascular and renal injury [J]. J Biol Chem, 2016, 291 (42): 22288.

This Article



Vol 45, No. 11, Pages 2595-2600

June 2020


Article Outline



  • 1 Materials
  • 2 Methods
  • 3 Results
  • 4 Discussion
  • References